Nectar Lifesciences has received approval to acquire 100% paid-up equity share capital of Avensis Exports (AEPL). The proposed acquisition of AEPL will help the company to enter into a real estate business. AEPL’s exposures in land and collaborations with other real estate companies will help the company to set its footprints in the real estate arena. This investment will allow the company to diversify, strengthen its position in the real estate business. The cost of the said acquisition is Rs 24.96 lakh and is expected to be completed within a period of 1 month.
Post acquisition, AEPL will become a wholly owned subsidiary of the company. The board of directors of the company in its meeting held on March 02, 2026, has, inter-alia, approved the same.
Nectar Lifesciences, Incorporated in 1995, is a leading global manufacturer of cephalosporin antibiotics medicines.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1820.75 |
| Dr. Reddys Lab | 1270.95 |
| Cipla | 1333.55 |
| Zydus Lifesciences | 911.85 |
| Lupin | 2343.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: